TSHA Annual Accounts Payable
$6.37 M
-$4.58 M-41.84%
31 December 2023
Summary:
As of January 23, 2025, TSHA annual accounts payable is $6.37 million, with the most recent change of -$4.58 million (-41.84%) on December 31, 2023. During the last 3 years, it has risen by +$4.37 million (+219.26%). TSHA annual accounts payable is now -70.75% below its all-time high of $21.76 million, reached on December 31, 2021.TSHA Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TSHA Quarterly Accounts Payable
$4.93 M
-$3.79 M-43.43%
30 September 2024
Summary:
As of January 23, 2025, TSHA quarterly accounts payable is $4.93 million, with the most recent change of -$3.79 million (-43.43%) on September 30, 2024. Over the past year, it has dropped by -$2.59 million (-34.41%). TSHA quarterly accounts payable is now -79.42% below its all-time high of $23.97 million, reached on June 30, 2022.TSHA Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TSHA Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -41.8% | -34.4% |
| 3 y3 years | +219.3% | -77.6% |
| 5 y5 years | +100.0% | - |
TSHA Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -70.8% | at low | -79.4% | at low |
| 5 y | 5-year | -70.8% | -79.4% | +294.6% | |
| alltime | all time | -70.8% | -79.4% | +294.6% |
Taysha Gene Therapies Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.93 M(-43.4%) |
| June 2024 | - | $8.72 M(-16.0%) |
| Mar 2024 | - | $10.38 M(+63.1%) |
| Dec 2023 | $6.37 M(-41.8%) | $6.37 M(-15.3%) |
| Sept 2023 | - | $7.52 M(-30.2%) |
| June 2023 | - | $10.77 M(+19.6%) |
| Mar 2023 | - | $9.00 M(-17.8%) |
| Dec 2022 | $10.95 M | $10.95 M(-28.2%) |
| Sept 2022 | - | $15.25 M(-36.4%) |
| June 2022 | - | $23.97 M(+9.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $22.00 M(+1.1%) |
| Dec 2021 | $21.76 M(+991.4%) | $21.76 M(-1.3%) |
| Sept 2021 | - | $22.05 M(+247.0%) |
| June 2021 | - | $6.36 M(+55.6%) |
| Mar 2021 | - | $4.08 M(+104.8%) |
| Dec 2020 | $1.99 M(>+9900.0%) | - |
| Dec 2020 | - | $1.99 M(-77.4%) |
| Sept 2020 | - | $8.84 M(+607.0%) |
| June 2020 | - | $1.25 M |
| Dec 2019 | $0.00 | - |
FAQ
- What is Taysha Gene Therapies annual accounts payable?
- What is the all time high annual accounts payable for Taysha Gene Therapies?
- What is Taysha Gene Therapies annual accounts payable year-on-year change?
- What is Taysha Gene Therapies quarterly accounts payable?
- What is the all time high quarterly accounts payable for Taysha Gene Therapies?
- What is Taysha Gene Therapies quarterly accounts payable year-on-year change?
What is Taysha Gene Therapies annual accounts payable?
The current annual accounts payable of TSHA is $6.37 M
What is the all time high annual accounts payable for Taysha Gene Therapies?
Taysha Gene Therapies all-time high annual accounts payable is $21.76 M
What is Taysha Gene Therapies annual accounts payable year-on-year change?
Over the past year, TSHA annual accounts payable has changed by -$4.58 M (-41.84%)
What is Taysha Gene Therapies quarterly accounts payable?
The current quarterly accounts payable of TSHA is $4.93 M
What is the all time high quarterly accounts payable for Taysha Gene Therapies?
Taysha Gene Therapies all-time high quarterly accounts payable is $23.97 M
What is Taysha Gene Therapies quarterly accounts payable year-on-year change?
Over the past year, TSHA quarterly accounts payable has changed by -$2.59 M (-34.41%)